Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sotio Biotech Inc.
Dana-Farber Cancer Institute
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
Shattuck Labs, Inc.
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)
Transgene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Elicio Therapeutics
Institut Bergonié
UNC Lineberger Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Sichuan Enray Pharmaceutical Sciences Company
University of Kentucky
Pfizer
University of Pennsylvania
Black Diamond Therapeutics, Inc.
University of Pennsylvania
Boehringer Ingelheim
Shattuck Labs, Inc.
Washington University School of Medicine
BeiGene
Duke University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sandoz
Pfizer
Kazia Therapeutics Limited
Avera McKennan Hospital & University Health Center
Pfizer
ADC Therapeutics S.A.
Advaxis, Inc.
Pfizer
Tesaro, Inc.
Eli Lilly and Company
Gilead Sciences
AIDS Malignancy Consortium
EMD Serono
National Cancer Institute (NCI)
Mayo Clinic
Pfizer
University Hospital, Ghent
Hoffmann-La Roche
Brown University
Ludwig Institute for Cancer Research